The drug candidate, trevogrumab, in combination with Novo Nordisk's popular obesity drug Wegovy, chemically known as semaglutide, helped patients preserve muscle and increase fat loss in patients, ...

Retail investor sentiment around Hims & Hers Health remained negative over the weekend after the telehealth firm confirmed it ...

Recent health news includes a promising AstraZeneca pill for breast cancer treatment, Pfizer and Arvinas' experimental drug ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

If you are looking to get a weight loss drug but lack insurance coverage, telehealth websites such as Ro, Hers and Mochi Health sell GLP-1 drugs for lower prices than what you’d pay at a pharmacy, ...

HIMS showcases outstanding financial strength. With just $63 million in debt against a market value of $13 billion, the ...

Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S ...

Hims & Hers Health Inc. is cutting more than 4% of its workforce as it pivots away from selling cheap copycat versions of ...

In the wake of sweeping cuts at the FDA’s Office of Prescription Drug Promotion (OPDP), Sen. | In the wake of sweeping cuts ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

Novo Nordisk warned the US government not to impose pharma-specific tariffs, but instead to tax illegal importers of ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...